IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market
- New science-backed formulations designed to support cellular health, energy metabolism, and cognitive function -
POTOMAC, MD / ACCESS Newswire / February 20, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is expanding its Holiby™ wellness brand with the launch of two new product lines-Longevity and Renew-specifically designed to meet the increasing demand for anti-aging and cellular health solutions.
Holiby is scaling its commercial strategy through direct-to-consumer e-commerce, white-label and private-label partnerships, and targeted influencer marketing and digital advertising. This multi-channel approach positions Holiby for growth while expanding IGC Pharma's non-dilutive revenue streams.
The expansion of Holiby complements IGC Pharma's broader mission of advancing science-backed health solutions, including clinical-stage drug development for Alzheimer's and neurodegenerative diseases. The Company is currently progressing IGC-AD1, its investigational Alzheimer's therapy, through a Phase 2 clinical trial ("CALMA") while also exploring new drug candidates in metabolic and neurodegenerative disorders. The nutraceutical and pharmaceutical segments serve parallel markets, enabling IGC to leverage its research expertise, consumer insights, and distribution network to build a comprehensive health-focused portfolio.
"Longevity and Renew represent a strategic move into the high-growth anti-aging market," said Ram Mukunda, CEO of IGC Pharma. "By leveraging cutting-edge research and scalable manufacturing, we're not only delivering best-in-class products, but also unlocking new revenue opportunities for Holiby through direct sales and white-label partnerships. This expansion aligns with our vision of merging science and wellness to create long-term value for both consumers and shareholders."
The global longevity and anti-aging market is projected to exceed $182 billion by 2028, with consumers increasingly prioritizing cellular health, cognitive function, and sustained energy. Holiby's science-backed formulations are designed to naturally support NAD+ levels, a key molecule in metabolism and cellular repair that declines with age, impacting energy, mental clarity, and overall vitality.
The new products include:
Longevity Gummies - Cognitive & Cellular Health Support
Renew Gummies - Energy & Resilience
Holiby's consumer-first approach prioritizes clean-label, science-driven formulations, appealing to a growing audience of health-conscious professionals, entrepreneurs, fitness enthusiasts, and wellness advocates aged 40+. As Holiby continues to gain traction, IGC Pharma is positioned to capture market share in the booming anti-aging, longevity, and cognitive health sectors, further reinforcing the Company's commitment to innovation and strategic revenue growth.
Holiby's Longevity & Renew products are available now.
Visit us at: https://holiby.us/
About IGC Pharma (dba IGC):
IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia ("CALMA") associated with Alzheimer's (clinicaltrials.gov, IGC Pharma Phase II). Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 32 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions. The Company operates a wellness brand offering scientifically formulated products under the brand Holiby™ and as white-labeled formulations.
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Q filed with the SEC on August 7, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
4 hours ago
- Cision Canada
iGan Partners Leads Seed+ Financing for Cosm Medical to Advance Personalized Gynecological Devices
TORONTO, June 5, 2025 /CNW/ - iGan Partners is pleased to announce that it has led the first close of a Seed+ financing round for Cosm Medical, a medical device company modernizing pelvic health through personalized gynecological care. The round included new investor Spring Impact Capital and several angels, and will support Cosm's U.S. expansion, clinical validation, and commercial growth. Cosm's flagship platform, Gynethotics TM, combines medical imaging, AI-driven design software, and 3D printing to create custom vaginal devices – starting with pessaries – tailored to each patient's unique anatomy and needs. The solution addresses a widespread but underserved women's health issue: pelvic floor disorders, which affect up to half of all women in their lifetime. "Cosm is modernizing a long-overlooked space in women's health through a personalized, data-driven platform grounded in precision care," said Sam Ifergan, Founding Partner at iGan Partners. "We're excited to support their mission to improve outcomes and quality of life for millions of women." "At Cosm, we're not just building a product—we're redefining an entire category of women's health. Our Gynethotics™ platform is more than just technology; it's a commitment to precision, personalization, and dignity in care. With the support of iGan Partners and our investors, we're accelerating a future where women are no longer underserved – where every solution is tailored, and true innovation means changing lives. This is just the beginning." – Derek Sham, Founder & CEO of Cosm Medical. "We were impressed with Derek's experience in commercializing medical devices, as well as COSM's extraordinary team, depth of intellectual property and thoughtfulness of the go-to-market strategy, said Olivia Hornby, Managing Partner at Spring Impact Capital. "As impact investors, we were excited by COSM's mission of building customized and data centric Gynethotics solutions – providing better care for the huge percentage of women who suffer from pelvic floor disorders. Gynethotics TM pessaries are approved for sale in both Canada and the U.S., and Cosm is actively expanding its presence across North America. The company is also building its clinical dataset and advancing its product pipeline to support new applications beyond pessary support, including postpartum and post-surgical recovery. About Cosm Medical Cosm Medical is a medical device company developing a hardware and software platform to personalize the treatment of pelvic floor disorders (PFDs), such as incontinence and pelvic organ prolapse. Its first product, Gynethotics TM, is a made-to-measure gynecological prosthetics platform that combines imaging, AI, and 3D printing to improve pessary performance, enhance patient comfort, and reduce complications. Cosm is redefining care for a long-overlooked area of women's health through precision medicine and digital innovation. Learn more at About iGan Partners iGan Partners is a North American venture capital firm focused on investing in emerging leaders in medical technology and digital health. We partner with founders building transformative solutions to improve patient outcomes, reduce system inefficiencies, and enable the future of data-driven care. iGan provides capital and strategic support to early commercial-stage companies across MedTech, digital health, diagnostics, and health IT. Our team brings deep sector expertise, a strong cross-border network, and a track record of scaling healthcare ventures from early growth to successful exit. Learn more at
Cision Canada
7 hours ago
- Cision Canada
Biogen Disappointed by INESSS Recommendation on SKYCLARYS™ and its Impact on Quebec Patients with Friedreich Ataxia Français
TORONTO, June 5, 2025 /CNW/ - Biogen Canada Inc. is disappointed by INESSS's recommendation against listing SKYCLARYS™ (omaveloxolone), despite its therapeutic potential for individuals living with Friedreich ataxia (FA) — a community in urgent need of treatment options. A decision to not reimburse SKYCLARYS would leave individuals living with FA in Quebec without public access to the only approved treatment for this rare, progressive, and life-shortening neurodegenerative disease – despite a clear and ongoing medical need. 1 As the only approved treatment targeting disease progression, SKYCLARYS addresses a long-standing gap in care for Canadians living with FA, particularly in Quebec where a notable concentration of cases highlights the importance of equitable access. 2 "After years of research and failed trials with no approved treatments until now, the availability of a therapy with a demonstrated ability to slow disease progression and preserve mobility is profoundly meaningful for the Friedreich ataxia community, offering renewed hope and the possibility of managing the disease and care in FA. We remain committed to working with INESSS, government authorities, and clinicians to help ensure access to SKYCLARYS for eligible FA patients in Quebec and the rest of Canada," said Eric Tse, General Manager, Biogen Canada. SKYCLARYS was approved in March 2025 under Health Canada's Priority Review process as the first and only treatment in Canada to target the underlying mechanisms of FA in patients aged 16 and older. Canada's Drug Agency (CDA-AMC), which advises on drug reimbursement across Canada's public drug programs outside of Quebec, has issued a positive draft recommendation recognizing SKYCLARYS as an important therapeutic option, valued by patients, caregivers, and clinicians for its potential to improve quality of life and preserve function. 3 About SKYCLARYS™ (omaveloxolone) SKYCLARYS™ (omaveloxolone) is an oral, once-daily medication indicated for the treatment of Friedreich ataxia (FA) in adults and adolescents aged 16 years and older in the United States (U.S.), European Union and Canada. 4,5,6 SKYCLARYS received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA). 5 The European Commission granted Orphan Drug designation in Europe to SKYCLARYS for the treatment of FA. 6 In Canada, marketing authorization for SKYCLARYS was granted under the Health Canada Priority Review process. 7 Biogen continues to be dedicated to advancing research and development efforts to enhance the understanding of FA and improve patient outcomes. This includes an ongoing, open-label, Phase 1 study to evaluate the use of SKYCLARYS in in pediatric patients aged 2 to 15 years. More details can be found at About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment, to deliver long-term growth. Biogen has been proudly serving Canadian patients for more than 25 years. For information about Biogen Canada, please visit
Cision Canada
a day ago
- Cision Canada
Dime Community Bank Selects Quantifind to Strengthen Sanctions Screening in Payments
PALO ALTO, Calif., June 4, 2025 /CNW/ -- Dime Community Bancshares, Inc., the holding company for Dime Community Bank, a New York State-chartered trust company with over $14 billion in assets and the number one deposit market share among community banks on Greater Long Island (1), has chosen Quantifind's AI-powered risk intelligence platform to enhance its sanctions screening for payments. Faced with increasing regulatory scrutiny and growing complexity in global transactions, Dime sought a more precise and scalable solution to strengthen its compliance program while maintaining efficient operations. After a competitive evaluation, Dime selected Quantifind for its advanced capabilities in risk detection and seamless integration into existing workflows. "Our partnership with Quantifind represents a significant advancement in our compliance capabilities," said Michael Fegan, CTO, Dime Community Bank. "Quantifind's AI-driven platform equips us to protect our customers and communities while maintaining the highest standards of regulatory compliance." "We're proud to partner with Dime Community Bank and extend our support to mid-market banks that are critical to the financial ecosystem," said Graham Bailey, Quantifind COO. "Quantifind's solutions are designed to empower banks of all sizes to tackle financial crime with unparalleled speed, accuracy, and scalability." Quantifind's commitment to supporting mid-market banks reflects a broader mission to deliver purpose-built AI solutions that help institutions of all sizes detect and mitigate financial crime risks. About Dime Community Bank Dime Community Bank, headquartered in Hauppauge, New York, has served its community since 1864. With over 60 locations across the New York metropolitan area, which includes the five boroughs, Long Island, and Westchester County, Dime offers a comprehensive range of financial services for individuals and businesses. About Quantifind Quantifind is a leader in financial crime intelligence automation. Its Graphyte™ platform delivers real-time, accurate risk assessments by integrating internal data with unstructured public information, enabling organizations to uncover hidden threats and strengthen compliance with speed, accuracy, and scale. ¹ Aggregate deposit market share for Kings, Queens, Nassau & Suffolk counties for community banks with less than $20 billion in assets. Forward-Looking Statements Statements contained in this news release that are not historical facts are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those currently anticipated. Media Contact Annalisa Camarillo EVP of Marketing, Quantifind Email: [email protected] SOURCE Quantifind
